BACKGROUND: The early and intermediate outcome of patients requiring intraaortic balloon pump (IABP) was studied in a cohort of 2697 adult cardiac surgical patients. METHODS: 136 patients requiring IABP (5.04%) support analysed over a 4 year period. Prospective data collection, obtained. RESULTS: The overall operative mortality was 35.3%. The "operation specific" mortality was higher on the Valve population.The mortality (%) as per time of balloon insertion was: Preoperative 18.2, Intraoperative 33.3, postoperative 58.3 (p < 0.05).The incremental risk factors for death were: Female gender (Odds Ratio (OR) = 3.87 with Confidence Intervals (CI) = 1.3-11.6), Smoking (OR = 4.88, CI = 1.23- 19.37), Preoperative Creatinine>120 (OR = 3.3, CI = 1.14-9.7), Cross Clamp time>80 min (OR = 4.16, CI = 1.73-9.98) and IABP insertion postoperatively (OR = 19.19, CI = 3.16-116.47).The incremental risk factors for the development of complications were: Poor EF (OR = 3.16, CI = 0.87-11.52), Euroscore >7 (OR = 2.99, CI = 1.14-7.88), history of PVD (OR = 4.99, CI = 1.32-18.86).The 5 years survival was 79.2% for the CABG population and 71.5% for the valve group. (Hazard ratio = 1.78, CI = 0.92-3.46). CONCLUSIONS: IABP represents a safe option of supporting the failing heart. The need for IABP especially in a high risk Valve population is associated with early unfavourable outcome, however the positive mid term results further justify its use.
BACKGROUND: The early and intermediate outcome of patients requiring intraaortic balloon pump (IABP) was studied in a cohort of 2697 adult cardiac surgical patients. METHODS: 136 patients requiring IABP (5.04%) support analysed over a 4 year period. Prospective data collection, obtained. RESULTS: The overall operative mortality was 35.3%. The "operation specific" mortality was higher on the Valve population.The mortality (%) as per time of balloon insertion was: Preoperative 18.2, Intraoperative 33.3, postoperative 58.3 (p < 0.05).The incremental risk factors for death were: Female gender (Odds Ratio (OR) = 3.87 with Confidence Intervals (CI) = 1.3-11.6), Smoking (OR = 4.88, CI = 1.23- 19.37), Preoperative Creatinine>120 (OR = 3.3, CI = 1.14-9.7), Cross Clamp time>80 min (OR = 4.16, CI = 1.73-9.98) and IABP insertion postoperatively (OR = 19.19, CI = 3.16-116.47).The incremental risk factors for the development of complications were: Poor EF (OR = 3.16, CI = 0.87-11.52), Euroscore >7 (OR = 2.99, CI = 1.14-7.88), history of PVD (OR = 4.99, CI = 1.32-18.86).The 5 years survival was 79.2% for the CABG population and 71.5% for the valve group. (Hazard ratio = 1.78, CI = 0.92-3.46). CONCLUSIONS: IABP represents a safe option of supporting the failing heart. The need for IABP especially in a high risk Valve population is associated with early unfavourable outcome, however the positive mid term results further justify its use.
Authors: Jan T Christenson; Marc Cohen; James J Ferguson; Robert J Freedman; Michael F Miller; E Magnus Ohman; Ramachandra C Reddy; Gregg W Stone; Philip M Urban Journal: Ann Thorac Surg Date: 2002-10 Impact factor: 4.330
Authors: Ian R Ramnarine; Antony D Grayson; Walid C Dihmis; Neeraj K Mediratta; Brian M Fabri; John A C Chalmers Journal: Eur J Cardiothorac Surg Date: 2005-05 Impact factor: 4.191
Authors: Corstiaan A den Uil; Suzanne D A Valk; Jin M Cheng; Arie P Kappetein; Ad J J C Bogers; Ron T van Domburg; Maarten L Simoons Journal: Interact Cardiovasc Thorac Surg Date: 2009-05-15
Authors: K S Naunheim; M T Swartz; D G Pennington; A C Fiore; L R McBride; P S Peigh; M G Barnett; K J Vaca; G C Kaiser; V L Willman Journal: J Thorac Cardiovasc Surg Date: 1992-12 Impact factor: 5.209
Authors: Yang Li; Ran Dong; Kun Hua; Tao-Shuai Liu; Shao-You Zhou; Ning Zhou; Hong-Jia Zhang Journal: Chin Med J (Engl) Date: 2017-12-20 Impact factor: 2.628
Authors: Yücel Özen; Mehmet Aksut; Davut Cekmecelioglu; Mehmet Dedemoglu; Ozge Altas; Sabit Sarikaya; Murat Bulent Rabus; Kaan Kirali Journal: J Cardiovasc Thorac Res Date: 2018-09-24